Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)








BISMUTH TELLURIDE						Print
																Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 1304-82-1; **Chemical Formula:** Bi2Te3
OSHA had no former limit for doped bismuth telluride (Bi(2)Te(3)). The ACGIH has a TLV-TWA of 5 mg/m3 for Bi(2)Te(3) that has been doped with selenium sulfide. The proposed PEL was 5 mg/m3 as an 8-hour TWA; NIOSH (Ex. 8-47, Table N1) concurs with this limit, and the final rule establishes it. Bismuth telluride appears as gray, hexagonal platelets; it is also available as ingots or single crystals.
Wagner, Madden, Zimber, and Stokinger (1974, as cited in ACGIH 1986/Ex. 1-3, p. 59) conducted a one-year study in which rabbits, dogs, and rats were exposed for six hours/day, five days/week to doped bismuth telluride dust (containing 80.04 mol % Bi2Te3 and 0.20 mol % SnTe, plus a small stoichiometric excess of Te) of 1.04 um particle diameter at a mean concentration of 15 mg/m3. Small, granulomatous lesions without fibrosis appeared in the lungs of dogs at six months. In dogs that were sacrificed four months after an eight-month exposure, the lesions had regressed, and the affected lymph nodes were without cellular reaction. Rabbits exhibited similar histologic effects, but with decreased numbers of pulmonary macrophages, no fibrous tissue proliferation, and no cellular or fibrous tissue reaction around the dust deposits in the lymph nodes. The rats showed fewer granulomas but some areas of epithelialization of the alveolar walls. As was true for the other species, the rats showed neither fibrosis nor cellular reaction in the lymph nodes, despite accumulation of the intermetallic dust (Wagner, Madden, Zimber, and Stokinger 1974, as cited in ACGIH 1986/Ex. 1-3, p. 59). Only NIOSH commented on this substance.
In the final rule, an 8-hour PEL of 5 mg/m3 TWA is established for Se-doped bismuth telluride to prevent the occurrence of the pulmonary lesions seen in experimental animals. OSHA concludes that this limit will substantially reduce the significant risk of these pulmonary effects.
							
					
							Last Reviewed:  September 28, 2011						Source: 	National Institute for Occupational Safety and Health
					Facebook
        Twitter
        LinkedIn
        Syndicate NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue